» Articles » PMID: 36683600

Biomarkers for Predicting the Occurrence and Progression of Atrial Fibrillation: Soluble Suppression of Tumorigenicity 2 Protein and Tissue Inhibitor of Matrix Metalloproteinase-1

Overview
Publisher Wiley
Specialty General Medicine
Date 2023 Jan 23
PMID 36683600
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Soluble suppression of tumorigenicity 2 protein (sST2) and tissue inhibitor of matrix metalloproteinase (TIMP)-1 are involved in multiple pathogenic pathways, including cardiac remodeling, which is the main pathology of atrial fibrillation (AF). This study aims to investigate the previously unexplored relationship between the serum levels of sST2, TIMP-1, and AF.

Methods: This was a prospective cross-sectional study conducted at the Capital Medical University Affiliated Beijing Anzhen Hospital between June 2019 and July 2020, with a total of 359 participants. The clinical characteristics and laboratory results of the patients were compared, and multivariable ordinal logistic regression was used to evaluate the relationship between serum sST2, TIMP-1, and AF.

Results: The participants included 110 patients with sinus rhythm (SR), 113 with paroxysmal AF (the paroxysmal AF group), and 136 with persistent AF (the persistent AF group). It was found that the sST2 levels gradually increased in these three groups, from 9.1 (6.7-12.4 pg/ml) in the SR group to 14.0 (10.4-20.8 pg/ml) in the paroxysmal AF group and to 19.0 (13.1-27.8) pg/ml) in the persistent AF group (  <  0.001). The multivariable ordinal logistic regression model for sST2 and TIMP-1 demonstrated that sST2 had an area under the receiver operating characteristic (ROC) curve (AUC) of 0.797 (95% confidence interval (CI) 0.749-0.846,   <  0.001) and TIMP-1 had an AUC of 0.795 (95% CI 0.750-0.841, =0.000). The multivariable ordinal logistic regression model for sST2 and TIMP-1 showed good discrimination between SR and AF, with an AUC of 0.846, and the addition of clinical factors, such as brain natriuretic peptide (BNP), left atrial diameter, age, and gender, to the biomarker model improved the detection of SR and AF (AUC 0.901).

Conclusions: In this cohort study, sST2 and TIMP-1 were associated with AF progression, independent of clinical characteristics and biomarkers. Soluble ST2 and TIMP-1 combined with age, elevated N-terminal-pro hormone BNP(NT-BNP), and an enlarged left atrium were able to demonstrate the progression of AF reliably.

Citing Articles

Atrial Fibrosis in Atrial Fibrillation: Mechanistic Insights, Diagnostic Challenges, and Emerging Therapeutic Targets.

Karakasis P, Theofilis P, Vlachakis P, Korantzopoulos P, Patoulias D, Antoniadis A Int J Mol Sci. 2025; 26(1.

PMID: 39796066 PMC: 11720255. DOI: 10.3390/ijms26010209.


Translation of pathophysiological mechanisms of atrial fibrosis into new diagnostic and therapeutic approaches.

Schotten U, Goette A, Verheule S Nat Rev Cardiol. 2024; .

PMID: 39443702 DOI: 10.1038/s41569-024-01088-w.


Atrial cardiomyopathy revisited-evolution of a concept: a clinical consensus statement of the European Heart Rhythm Association (EHRA) of the ESC, the Heart Rhythm Society (HRS), the Asian Pacific Heart Rhythm Society (APHRS), and the Latin American....

Goette A, Corradi D, Dobrev D, Aguinaga L, Cabrera J, Chugh S Europace. 2024; 26(9).

PMID: 39077825 PMC: 11431804. DOI: 10.1093/europace/euae204.


Predictive value of soluble suppression of tumorigenicity 2 in atrial fibrillation: a systematic review and meta-analysis.

Chen P, Zhang J, Du J, Shi D, Zhang H Front Cardiovasc Med. 2024; 10:1308166.

PMID: 38274310 PMC: 10808625. DOI: 10.3389/fcvm.2023.1308166.


The Role of Biochemical Cardiac Markers in Atrial Fibrillation.

Rafaqat S, Rafaqat S, Ijaz H J Innov Card Rhythm Manag. 2023; 14(10):5611-5621.

PMID: 37927395 PMC: 10621624. DOI: 10.19102/icrm.2023.14101.


References
1.
Ravassa S, Ballesteros G, Lopez B, Ramos P, Bragard J, Gonzalez A . Combination of Circulating Type I Collagen-Related Biomarkers Is Associated With Atrial Fibrillation. J Am Coll Cardiol. 2019; 73(12):1398-1410. DOI: 10.1016/j.jacc.2018.12.074. View

2.
Allan V, Honarbakhsh S, Casas J, Wallace J, Hunter R, Schilling R . Are cardiovascular risk factors also associated with the incidence of atrial fibrillation? A systematic review and field synopsis of 23 factors in 32 population-based cohorts of 20 million participants. Thromb Haemost. 2017; 117(5):837-850. PMC: 5442605. DOI: 10.1160/TH16-11-0825. View

3.
Kalstad A, Myhre P, Laake K, Opstad T, Tveit A, Solheim S . Biomarkers of ageing and cardiac remodeling are associated with atrial fibrillation. Scand Cardiovasc J. 2021; 55(4):213-219. DOI: 10.1080/14017431.2021.1889653. View

4.
Geelhoed B, Borschel C, Niiranen T, Palosaari T, Havulinna A, Fouodo C . Assessment of causality of natriuretic peptides and atrial fibrillation and heart failure: a Mendelian randomization study in the FINRISK cohort. Europace. 2020; 22(10):1463-1469. PMC: 7544535. DOI: 10.1093/europace/euaa158. View

5.
Tanaka M, Imano H, Kubota Y, Yamagishi K, Umesawa M, Muraki I . Serum High-Sensitivity C-Reactive Protein Levels and the Risk of Atrial Fibrillation in Japanese Population: the Circulatory Risk in Communities Study. J Atheroscler Thromb. 2020; 28(2):194-202. PMC: 7957035. DOI: 10.5551/jat.54064. View